SCHEMBL15919447

SCHEMBL15919447

Oc1cc(-c2ccc(Br)cc2)nc2ccncc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
EPRS1 P07814 3/20 0.46
ESR1 P03372 3/20 0.44
ESR2 Q92731 3/20 0.44
ESRRB O95718 1/20 0.44
ESRRA P11474 1/20 0.44
RXFP1 Q9HBX9 2/20 0.43
PRNP P04156 1/20 0.42
PPARG P37231 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NR2E3 Q9Y5X4 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
CDC7 O00311 1/20 0.41
MCL1 Q07820 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
P4HB P07237 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4849623 0.86 DHODH (0.48) KMT2AMEN1NPSR1CDC7ALDH1A1
SCHEMBL4852658 0.85 MAPK1 (0.47) ESR1ESR2ESRRBESRRACDC7
SCHEMBL4857363 0.85 ALDH1A1 (0.48) KMT2AMEN1CDC7ALDH1A1GAA
SCHEMBL15919444 0.84 ALDH1A1 (0.47) KMT2AMEN1CDC7ALDH1A1GAA
SCHEMBL4846980 0.82 METAP1 (0.38) KMT2AMEN1ESR1ESR2RXFP1
SCHEMBL15905152 0.82 SLC2A1 (0.55) KMT2AMEN1EPRS1RXFP1PRNP
SCHEMBL15905102 0.81 EPRS1 (0.64) KMT2AMEN1EPRS1ALDH1A1GAA
SCHEMBL18455618 0.81 KMT2A (0.52) KMT2AMEN1RXFP1PRNPPPARG
SCHEMBL16098115 0.80 POLB (0.51) KMT2AMEN1EPRS1ESR1ESR2
SCHEMBL15919411 0.79 KMT2A (0.53) KMT2AMEN1EPRS1RXFP1PRNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO KMT2A 1886/4885MEN1 511/4885EPRS1 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.